Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6218675 | 1.00 | SLC7A5 (0.54) | SLC7A5ALDH1A1POLBIDO1MAOB | |
| SCHEMBL28637433 | 1.00 | SLC7A5 (0.54) | SLC7A5ALDH1A1POLBIDO1MAOB | |
| Hydrochloric Acid SCHEMBL32677180 | 0.98 | SLC7A5 (0.52) | SLC7A5ALDH1A1POLBIDO1MAOB | |
| Hydrochloric Acid SCHEMBL32676955 | 0.98 | SLC7A5 (0.52) | SLC7A5ALDH1A1POLBIDO1MAOB | |
| Hydrochloric Acid SCHEMBL32676895 | 0.98 | SLC7A5 (0.52) | SLC7A5ALDH1A1POLBIDO1MAOB | |
| SCHEMBL27762534 | 0.88 | ALDH1A1 (0.50) | SLC7A5ALDH1A1POLBIDO1MAOB | |
| SCHEMBL20543766 | 0.88 | ALDH1A1 (0.50) | SLC7A5ALDH1A1POLBIDO1MAOB | |
| SCHEMBL21117864 | 0.88 | ALDH1A1 (0.50) | SLC7A5ALDH1A1POLBIDO1MAOB | |
| SCHEMBL13344379 | 0.86 | MAOB (0.61) | ALDH1A1POLBMAOB | |
| SCHEMBL28940615 | 0.85 | TAAR1 (0.47) | ALDH1A1POLBIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669242-B2 | Clostridium difficile toxin inhibitors | Venenum Biodesign, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | Venenum Biodesign, LLC (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2017214359-A1 | NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS | VENENUM BIODESIGN LLC (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | GABRA5, GABRA1, GABRA4 | SLC7A5 1616/4885ALDH1A1 2381/4885POLB 4138/4885 |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | GABRA5, GABRA1, GABBR2 | SLC7A5 1864/4885ALDH1A1 1908/4885POLB 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.